CTLA4 and myocarditis: These findings are consistent with evidence from clinical trials, which indicate that CTLA-4 inhibition is particularly associated with an increased risk of immune-mediated cardiotoxicity, which encompasses conditions such as pericarditis and myocarditis (157, 158).